CoChat

PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin

Open access
O’Brien, Matthew J., Perez, Alberly, Scanlan, Adam B., Alos, Victor A., Whitaker, Robert C., Foster, Gary D., Ackermann, Ronald T., Ciolino, Jody D., Homko, Carol · 2017 · American Journal of Preventive Medicine
Cited by 77

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Introduction Although the Diabetes Prevention Program and other clinical trials demonstrated the efficacy of intensive lifestyle interventions (ILI) and metformin to prevent Type 2 diabetes, no studies have tested their comparative effects in pragmatic settings. This study was designed to compare the real-world effectiveness of ILI, metformin, and standard care among Hispanic women (Latinas) with prediabetes. Study design RCT. Setting/participants Ninety-two Latinas, who had a mean hemoglobin A1c of 5.9%, BMI of 33.3 kg/m2, and waist circumference of 97.4 cm, were recruited from an urban community and randomly assigned to ILI, metformin, or standard care using 1:1:1 allocation. Data were collected from 2013–2015 and analyzed in 2016. Intervention The 12-month ILI was adapted from the Diabetes Prevention Program’s ILI and delivered by community health workers (promotoras) over 24 sessions. Metformin participants received 850 mg twice daily. Those randomized to standard care continued their regular medical care. Main outcome measures Weight and secondary outcomes (waist circumference, blood pressure, hemoglobin A1c, fasting plasma glucose, insulin, and lipids) were assessed at baseline and 12 months. Results ILI participants demonstrated significantly greater mean weight loss (−4.0 kg, 5.0%) than metformin (−0.9 kg, 1.1%) and standard care participants (+0.8 kg, 0.9%) (p<0.001). The difference in weight loss between metformin and standard care was not significant. The ILI group experienced a greater reduction in waist circumference than standard care (p=0.001), and a marginal improvement in hemoglobin A1c compared with metformin and standard care (p=0.063). Conclusions In the first comparative effectiveness trial of diabetes prevention treatments, a 12-month ILI produced significantly greater weight loss than metformin and standard care among Latinas with prediabetes. These data suggest that ILI delivered by promotoras is an effective strategy for preventing diabetes in this high-risk group, which may be superior to metformin. Future pragmatic trials involving larger samples should examine differences in diabetes incidence associated with these treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.amepre.2017.01.008

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 77

Metadata

Authors
O’Brien, M. J., Perez, A., Scanlan, A. B., Alos, V. A., Whitaker, R. C., Foster, G. D., Ackermann, R. T., Ciolino, J. D., & Homko, C.
Venue
American Journal of Preventive Medicine
Publisher
Elsevier BV
Published
2017-06
Volume
52
Issue
6
Pages
788-797
ISSN
0749-3797 (ISSN-L)
OpenAlex
W2591557384
Cited by
77
References
19
FWCI
5.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin. https://app.cochat.ai/papers/10.1016/j.amepre.2017.01.008
The paper
O’Brien, M. J., Perez, A., Scanlan, A. B., Alos, V. A., Whitaker, R. C., Foster, G. D., Ackermann, R. T., Ciolino, J. D., & Homko, C. (2017). PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin. American Journal of Preventive Medicine. https://doi.org/10.1016/j.amepre.2017.01.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.